- Home
- AVNT vs PTGX Comparison
AVNT vs PTGX Comparison
Compare AVNT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNT
- PTGX
- Stock Information
- Founded
- AVNT 1927
- PTGX 2006
- Country
- AVNT United States
- PTGX United States
- Employees
- AVNT N/A
- PTGX N/A
- Industry
- AVNT Major Chemicals
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- AVNT Industrials
- PTGX Health Care
- Exchange
- AVNT Nasdaq
- PTGX Nasdaq
- Market Cap
- AVNT 3.4B
- PTGX 3.3B
- IPO Year
- AVNT 1993
- PTGX 2016
- Fundamental
- Price
- AVNT $34.21
- PTGX $53.00
- Analyst Decision
- AVNT Strong Buy
- PTGX Strong Buy
- Analyst Count
- AVNT 5
- PTGX 9
- Target Price
- AVNT $49.40
- PTGX $67.11
- AVG Volume (30 Days)
- AVNT 860.8K
- PTGX 923.4K
- Earning Date
- AVNT 08-01-2025
- PTGX 08-05-2025
- Dividend Yield
- AVNT 3.09%
- PTGX N/A
- EPS Growth
- AVNT N/A
- PTGX N/A
- EPS
- AVNT 1.08
- PTGX 0.86
- Revenue
- AVNT $3,238,000,000.00
- PTGX $207,801,000.00
- Revenue This Year
- AVNT $2.98
- PTGX N/A
- Revenue Next Year
- AVNT $4.17
- PTGX $53.09
- P/E Ratio
- AVNT $32.26
- PTGX $61.48
- Revenue Growth
- AVNT 3.58
- PTGX N/A
- 52 Week Low
- AVNT $27.86
- PTGX $32.50
- 52 Week High
- AVNT $54.68
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- AVNT 48.39
- PTGX 53.99
- Support Level
- AVNT $33.37
- PTGX $49.38
- Resistance Level
- AVNT $35.79
- PTGX $51.51
- Average True Range (ATR)
- AVNT 1.01
- PTGX 2.02
- MACD
- AVNT 0.19
- PTGX -0.39
- Stochastic Oscillator
- AVNT 59.28
- PTGX 46.09
About AVNT Avient Corporation
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.